User:Oreo Jain/sandbox

Christopher Gregg is a Canadian researcher, futurist, and entrepreneur. He is an associate professor in the Departments of Neurobiology & Anatomy and Human Genetics at the University of Utah School of Medicine, director of the Gregg Lab, and Chief Science Officer and co-founder of Storyline Health Inc.

Career
Gregg was an undergraduate at the University of Lethbridge where he received a B.Sc. in biochemistry before receiving his PhD from the University of Calgary in Canada in neural stem cell biology. While working with Samuel Weiss at the Hotchkiss Brain Institute, he received the University of Calgary Chancellor's Medal for recognition of his work on stem cells and regenerative therapies. This work led to his first biotech company; Stem Cell Therapeutics.

In 2006, Gregg moved to Harvard University as a postdoc, where he received a Human Frontiers Fellowship, working with Dr. Catherine Dulac in the Dulac Lab, developing RNASeq methods to distinguish the expression of paternal and maternal alleles in the brain.

In 2011, Gregg joined the University of Utah Departments of Neurobiology & Human Genetics, where he founded the Gregg Lab. He was awarded tenure in 2019. The Gregg Lab played an early role in the development of sequencing technologies used to study study allele-specific expression effects using RNA-seq. This work revealed genes that exhibit a maternal or paternal allele expression bias and uncovered forms of genomic imprinting and parental influence on brain gene expression, significantly shaping offspring behavior.

In 2019, Gregg co-founded Storyline Health Inc., an A.I. company using human behavior to discover and deliver biomarkers of health and disease.

Cancer
In 2018, Chris Gregg was diagnosed with terminal stage 4 metastatic cancer and given an estimated life expectancy of 18-24 months. In response to his diagnosis he reviewed scientific literature and became aware of a clinical trial conducted in Moffitt Cancer Center on patients with metastatic castrate-resistant prostate cancer showed outcomes that "show significant improvement over published studies and a contemporaneous population." Gregg created a consortium of oncologists and researchers from Moffitt, Huntsman Cancer Institute, and others to improve cancer care pathways based upon evolutionary and adaptive therapy with an additional goal of educating cancer patients. In 2022, Gregg revealed in a video that he had shown no evidence of disease (NED) for almost 3 years.

Research
Gregg's research interest lies at the intersection of genomics and behavior, genetic and epigenetic mechanisms in the brain that regulate motivated behaviors. Reesarch using mouse models has shown that gene expression directly affects behaviour and that A.I. can be used to find behavioural biomarkers.

Awards and recognition

 * In 2010, he was awarded the Eppendorf & Science Prize for Neurobiology.
 * In 2010, his work was chosen as one of the "Top 10 Breakthroughs of the Year" by the National Institutes of Mental Health.
 * In 2012, he was chosen to be a New York Stem Cell Foundation Robertson Investigator.

Bibliography (selected)

 * Bonthuis, Paul J.; Steinwand, Susan; Stacher Hörndli, Cornelia N.; Emery, Jared; Huang, Wei-Chao; Kravitz, Stephanie; Ferris, Elliott; Gregg, Christopher (8 March 2002). "Noncanonical genomic imprinting in the monoamine system determines naturalistic foraging and brain-adrenal axis functions". Cell Reports. 38 (10). Cambridge, Massachusetts: Cell Press: 110500. doi:10.1016/j.celrep.2022.110500. PMID 35263575. S2CID 247338020.
 * Kravitz, Stephanie N.; Gregg, Christopher (30 May 2019). "New subtypes of allele-specific epigenetic effects: implications for brain development, function and disease". Science Direct. 59 (Dec. 2019). Elsevier: 69–78. doi:10.1016/j.conb.2019.04.012. PMC 7476552. PMID 31153086.
 * Stacher Hörndli, C. N.; Wong, E.; Ferris, E.; Bennett, K.; Steinwand, S.; Rhodes, A. N.; Fletcher, P. T.; Gregg, C. (13 August 2019). "Complex Economic Behavior Patterns Are Constructed from Finite, Genetically Controlled Modules of Behavior". Cell Reports. 28 (7). Cambridge, Massachusetts: Cell Press: 1814–1829.e6. doi:10.1016/j.celrep.2019.07.038. PMC 7476553. PMID 31412249. 31412249.